气管镜下介入联合药物注射治疗中央型非小细胞肺癌疗效与安全性研究

Efficacy and safety of interventional therapy combined with drug injection under bronchoscope in the treatment of central non-small cell lung cancer

目的:评价气管镜下介入联合瘤体药物注射方法对于中央型非小细胞肺癌(non-small cell lung cancer,NSCLC)的有效性和安全性。方法:符合试验入排标准的64名患者,对纳入试验的患者按照1∶1的比例随机分配试验组和对照组,分别给予支气管镜下介入及局部注射顺铂、重组人血管内皮抑素联合含铂双药化疗与单纯含铂双药化疗,比较两组的疗效以及安全性。结果:与对照组相比,试验组患者Karnofsky功能状态(karnofsky performance status,KPS)评分、气促分级均得到明显改善(P<0.05)。试验组的治疗总有效率为78.12%,对照组的总有效率为37.5%,两组间比较差异具有统计学意义(P<0.05),两组生存情况比较差异有统计学意义(P<0.05)。结论:经支气管镜介入联合药物注射治疗中央型NSCLC临床疗效显著,能有效改善临床症状,提高患者生存质量。两组患者不良反应比较,无显著差异,值得推广应用。

AIM:To evaluate the efficacy and safe-ty of interventional therapy combined with tumor drug injection under bronchoscope for central non-small cell lung cancer(NSCLC).METHODS:Sixty-four patients who met the test admission criteria were randomly assigned to the experimental group and the control group according to the ratio of 1:1,and were given bronchoscopic interventional thera-py combined with local drug injection of recombi-nant human endostatin combined with platinum-containing dual-drug chemotherapy and platinum-containing dual-drug alone,respectively.The cura-tive efficiency and safety of the two groups were compared.RESULTS:Compared with the control group,the KPS score,dyspnea grading were signifi-cantly improved(P<0.05).The effective rate of the test group was 78.12%,which was higher than 37.5%in the control group,the difference between the two groups was significant(P<0.05).Moreover,there was also a significant difference in the 1-year survival rate between the experimental group and the control group(P<0.05).CONCLUSION:The treatment of central NSCLC by interventional thera-py combined with tumor drug injection through fi-beroptic bronchoscope has obvious clinical efficacy,which can effectively alleviate the clinical symp-toms and improve the quality of life of patients.There is no significant difference in adverse reac-tions between the two groups,and is worthy of popularization and application.